June 30, 2023 10:45 AM-11:45 AMCT
In-person
Lone Star A3 | Session Group 3a
Join us as we discuss Duchenne Research that is Impacting Downstream. This session will repeat at 12:00pm in the Lone Star Ballroom BCapricor Therapeutics (Cap-1002) Edgewise Therapeutics (EDG-5506) FibroGen (Pamrevlumab) Antisense Therapeutics (ATL1102) Cumberland Pharmaceuticals (Ifetroban)
Repeated:
June 30, 2023 12:00 PM-1:00 PMCT
In-person & virtual
Lone Star Ballroom B | Session Group 3b
Ann: MHRA approval for ATL1102 Phase IIb DMD clinical trial in UK, page-13
-
- There are more pages in this discussion • 17 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
8.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $72.12M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1212 | 8.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 8.3¢ | 238277 | 2 |
View Market Depth
| Last trade - 07.29am 17/07/2024 (20 minute delay) ? |
| PER (ASX) Chart |
Day chart unavailable